HOWARU library - Bifido

Arunachalam K, Gill H S, Chandra R K. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000; (54): 263-267.

Chiang B L, Sheih Y H, Wang L H, Liao C K, Gill H S. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and defenition of cellular immune responses. Eur J Clin Nutr 2000; (54): 849-855.

Gill H, Rutherfurd K J, Cross M L. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related imunological changes. J Clin Immunol 2001a; (21): 264-271.

Gill H, Rutherfurd K J, Cross M L, Gopal P K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001b; (74): 833-839.

Gill H S. Potential of using dietary lactic acid bacteria for enhancement of immunity. Dialogue 1999; (32): 6-11.

Gill H S, Darragh A J, Cross M L. Optimizing immunity and gut function in the elderly. J Nutr Health Aging 2001c; (5): 80-91.

Gill H S, Rutherfurd K J, Prasad J, Gopal P K. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 2000; (83): 167-176.

Gopal P, Dekker J, Prasad Y, Pillidge C J, Delabre M-L, Collett M. Development and commercialisation of Fonterra's probiotic strains. Aust J Dairy Technol 2005; (60): 173-182.

Gopal P, Prasad J, Gill H S. Effects of the consumption of Bifidobacterium lactis HN019 (DR10™) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutr Res 2003; (23): 1313-1328.

Gopal P K, Prasad J, Smart J, Gill H S. In vitro adherence properties of Lactoacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 2001a; (67): 207-216.

Gopal P K, Sullivan P A, Smart J B. Utilisation of galacto-oligosaccharides as selective substrates for growth by lactic acid bacteria including Bifidobacterium lactis DR10 and Lactobacillus rhmanosus DR20. Int Dairy J 2001b; (11): 19-25.

Ouwehand A C, Philipp S. Bifidobacterium lactis HN019; the good taste of health. Agrofood Ind Hi-Tech 2004; (15): 10-12.

Prasad J, Gill H, Smart J, Gopal P K. Selection and characterisation of Lactobacillus and  Bifidobacterium strains for use as probiotics. Int Dairy J 1998; (8): 993-1002.

Sazawal S, Dhingra U, Sarkar A, Dhingra P, Deb S, Marwah D, Menon V P, Kumar J, Black R E. Efficacy of milk fortified with a probiotic Bifidobacterium lactis (DR-10™)and prebiotic galacto-oligosaccharides in prevention of morbidity and on nutritional status. Asia Pac J Clin Nutr 2004; (13): S28.

Shu Q, Gill H S. A dietary probiotic (Bifidobacterium lactis 019) reduces the severity of Escherichia coli 0157:H7 infection in mice. Med Microbiol Immunol 2001; (189): 147-152.

Shu Q, Lin H, Rutherfurd K J, Fenwick S G, Prasad J, Gopal P K, Gill H S. Dietary Bifidobacterium lactis (HN019) Enhances resistance to oral Salmonella typhimurium infection in mice. Microbiol Immunol 2000; (44): 213-222.

Shu Q, Qu F, Gill H S. Probiotic treatment using Bifidobacterium lactis HN019 reduces weanling diarrhea associated with rotavirus and Escherichia coli infection in a piglet model. J Ped Gastroenterol Nutr 2001; (33): 171-177.

Shu Q, Qu F, Lin K, Rutherfurd K J, Zhou J, Gill H S. Bifidobacterium lactis HN019 enhances host immunity and resistance to gastrointestinal pathogens. In: Food microbiology and food safety into the next millenium. (Eds.Tuijtelaars ACJ, Samson RA, Rombouts FM, Notermans S). Wageningen, the Netherlands: Foundation Food Micro '99, 1999a; 858-861.

Shu Q, Zhou J S, Rutherfurd K J, Britles M J, Prasad J, Gopal P K, Gill H. Probiotic lactic acid bacteria (Lactobacillus acidophilus HN017, Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019) have no adverse effects on the health of mice. Int Dairy J 1999b; (9): 831-836.

Zhou J S, Gill H S. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. Int J Food Microbiol 2005; (103): 97-104.

Zhou J S, Gopal P K, Gill H S. Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. Int J Food Microbiol 2001; (63): 81-90.

Zhou J S, Pillidge C J, Gopal P K, Gill H S. Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains. Int J Food Microbiol 2005a; (98): 211-217.

Zhou J S, Rutherfurd K J, Gill H S. Inability of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 to induce human platelet aggregation in vitro. J Food Prot 2005b; (68): 2459-2464.

Zhou J S, Shu Q, Rutherfurd K J, Prasad J, Britles M J, Gopal P K, Gill H S. Safety assessment of potential probiotic lactic acid bacteria strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice. Int J Food Microbiol 2000a; (56): 87-96.

Zhou J S, Shu Q, Rutherfurd K J, Prasad J, Gopal P K, Gill H. Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria.Food Chem Toxicol 2000b; (38): 153-161.